Replies to post #9784 on Ariad Pharmaceuticals Inc fka ARIA

[biomaven0]

Interesting:

By inhibiting both T790M and the initial activating mutations, Avila drug candidates in the EMSI program offer the prospect of effective drug treatment for first and second-line NSCLC patients who have activating EGFR mutations. With sparing of the wild-type EGFR, the EMSI program could also offer a much improved therapeutic window (i.e. fewer side effects) compared to current therapies in a first-line setting.

Avila is the company with a BTK drug competitive with PCYC.

Peter